<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34819571</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>02</Day></DateCompleted><DateRevised><Year>2022</Year><Month>02</Month><Day>02</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Nov</Month><Day>24</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Neuron-specific enolase level is a useful biomarker for distinguishing amyotrophic lateral sclerosis from cervical spondylotic myelopathy.</ArticleTitle><Pagination><StartPage>22827</StartPage><MedlinePgn>22827</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">22827</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-021-02310-2</ELocationID><Abstract><AbstractText>The current study aimed to evaluate whether cerebrospinal fluid (CSF) neuron-specific enolase (NSE) levels are elevated in amyotrophic lateral sclerosis (ALS) and are effective in distinguishing ALS from cervical spondylotic myelopathy (CSM). We retrospectively evaluated 45 patients with ALS, 23 with CSM, 28 controls, and 10 with Parkinson's disease (PD) who underwent analysis of CSF NSE levels. The control group comprised patients aged above 45&#xa0;years who underwent lumbar puncture because of suspected neurological disorders that were ruled out after extensive investigations. CSF NSE levels were evaluated using the electro-chemiluminescent immunoassay. The ALS group had significantly higher CSF NSE levels than the CSM and control groups (P&#x2009;&lt;&#x2009;0.001 for both comparisons). The CSM, control, and PD groups did not significantly differ in terms of CSF NSE levels. A receiver-operating characteristic curve analysis was performed to assess the diagnostic value of CSF NSE levels in distinguishing ALS from CSM. The area under the curve for CSF NSE levels was 0.86. The optimal cutoff value was 17.7&#xa0;ng/mL, with a specificity of 87% and a sensitivity of 80%. Hence, CSF NSE levels are elevated in ALS and are effective in distinguishing ALS from CSM.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tsukahara</LastName><ForeName>Akihiro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Neurology, Department of Internal Medicine IV, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-machi, Takatsuki, Osaka, 569-8686, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hosokawa</LastName><ForeName>Takafumi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Neurology, Department of Internal Medicine IV, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-machi, Takatsuki, Osaka, 569-8686, Japan. takafumi.hosokawa@ompu.ac.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nishioka</LastName><ForeName>Daisuke</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Medical Statistics, Research and Development Center, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kotani</LastName><ForeName>Takuya</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Internal Medicine IV, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ishida</LastName><ForeName>Shimon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Neurology, Department of Internal Medicine IV, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-machi, Takatsuki, Osaka, 569-8686, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takeuchi</LastName><ForeName>Tohru</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Medical Statistics, Research and Development Center, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kimura</LastName><ForeName>Fumiharu</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Osaka Medical and Pharmaceutical University Mishima-Minami Hospital, Takatsuki, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arawaka</LastName><ForeName>Shigeki</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Neurology, Department of Internal Medicine IV, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-machi, Takatsuki, Osaka, 569-8686, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>11</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 4.2.1.11</RegistryNumber><NameOfSubstance UI="C000715382">ENO2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 4.2.1.11</RegistryNumber><NameOfSubstance UI="D010751">Phosphopyruvate Hydratase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007118" MajorTopicYN="N">Immunoassay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008163" MajorTopicYN="N">Luminescent Measurements</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010751" MajorTopicYN="N">Phosphopyruvate Hydratase</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055009" MajorTopicYN="N">Spondylosis</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>8</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>11</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>25</Day><Hour>6</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34819571</ArticleId><ArticleId IdType="pmc">PMC8613178</ArticleId><ArticleId IdType="doi">10.1038/s41598-021-02310-2</ArticleId><ArticleId IdType="pii">10.1038/s41598-021-02310-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hardiman O, van den Berg LH, Kiernan MC. Clinical diagnosis and management of amyotrophic lateral sclerosis. Nat. Rev. Neurol. 2011;7:639&#x2013;649. doi: 10.1038/nrneurol.2011.153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2011.153</ArticleId><ArticleId IdType="pubmed">21989247</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL, World Federation of Neurology Research Group on Motor Neuron, D El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph. Later. Scler Other Motor Neuron Disord. 2000;1:293&#x2013;299. doi: 10.1080/146608200300079536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobson RD, Goutman SA, Callaghan BC. Pearls &amp; Oy-sters: The importance of atypical features and tracking progression in patients misdiagnosed with ALS. Neurology. 2016;86:e136&#x2013;139. doi: 10.1212/WNL.0000000000002522.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000002522</ArticleId><ArticleId IdType="pmc">PMC4818562</ArticleId><ArticleId IdType="pubmed">27022179</ArticleId></ArticleIdList></Reference><Reference><Citation>Cellura E, Spataro R, Taiello AC, La Bella V. Factors affecting the diagnostic delay in amyotrophic lateral sclerosis. Clin. Neurol. Neurosurg. 2012;114:550&#x2013;554. doi: 10.1016/j.clineuro.2011.11.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clineuro.2011.11.026</ArticleId><ArticleId IdType="pubmed">22169158</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowland LP. Diagnosis of amyotrophic lateral sclerosis. J. Neurol. Sci. 1998;160(Suppl 1):S6&#x2013;24. doi: 10.1016/s0022-510x(98)00193-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0022-510x(98)00193-2</ArticleId><ArticleId IdType="pubmed">9851643</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams JR, Fitzhenry D, Grant L, Martyn D, Kerr DA. Diagnosis pathway for patients with amyotrophic lateral sclerosis: Retrospective analysis of the US Medicare longitudinal claims database. BMC Neurol. 2013;13:160. doi: 10.1186/1471-2377-13-160.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2377-13-160</ArticleId><ArticleId IdType="pmc">PMC4029731</ArticleId><ArticleId IdType="pubmed">24499173</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraemer M, Buerger M, Berlit P. Diagnostic problems and delay of diagnosis in amyotrophic lateral sclerosis. Clin. Neurol. Neurosurg. 2010;112:103&#x2013;105. doi: 10.1016/j.clineuro.2009.10.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clineuro.2009.10.014</ArticleId><ArticleId IdType="pubmed">19931253</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshor D, Klugh A, 3rd, Appel SH, Haverkamp LJ. Incidence and characteristics of spinal decompression surgery after the onset of symptoms of amyotrophic lateral sclerosis. Neurosurgery. 2005;57:984&#x2013;989. doi: 10.1227/01.neu.0000180028.64385.d3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1227/01.neu.0000180028.64385.d3</ArticleId><ArticleId IdType="pubmed">16284567</ArticleId></ArticleIdList></Reference><Reference><Citation>Sostarko M, Vranjes D, Brinar V, Brzovic Z. Severe progression of ALS/MND after intervertebral discectomy. J. Neurol. Sci. 1998;160(Suppl 1):S42&#x2013;46. doi: 10.1016/s0022-510x(98)00197-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0022-510x(98)00197-x</ArticleId><ArticleId IdType="pubmed">9851648</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto S, Swash M, de Carvalho M. Does surgery accelerate progression of amyotrophic lateral sclerosis? J. Neurol. Neurosurg. Psychiatry. 2014;85:643&#x2013;646. doi: 10.1136/jnnp-2013-305770.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2013-305770</ArticleId><ArticleId IdType="pubmed">23922387</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato K, Ishiguro Y, Suzuki F, Ito A, Semba R. Distribution of nervous system-specific forms of enolase in peripheral tissues. Brain Res. 1982;237:441&#x2013;448. doi: 10.1016/0006-8993(82)90455-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0006-8993(82)90455-3</ArticleId><ArticleId IdType="pubmed">7044473</ArticleId></ArticleIdList></Reference><Reference><Citation>Isgro MA, Bottoni P, Scatena R. Neuron-specific enolase as a biomarker: Biochemical and clinical aspects. Adv. Exp. Med. Biol. 2015;867:125&#x2013;143. doi: 10.1007/978-94-017-7215-0_9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-94-017-7215-0_9</ArticleId><ArticleId IdType="pubmed">26530364</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrmann M, et al. Protein S-100B and neuron specific enolase as early neurobiochemical markers of the severity of traumatic brain injury. Restor. Neurol. Neurosci. 1999;14:109&#x2013;114.</Citation><ArticleIdList><ArticleId IdType="pubmed">12671254</ArticleId></ArticleIdList></Reference><Reference><Citation>Pouw MH, et al. Structural biomarkers in the cerebrospinal fluid within 24 h after a traumatic spinal cord injury: A descriptive analysis of 16 subjects. Spinal Cord. 2014;52:428&#x2013;433. doi: 10.1038/sc.2014.26.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sc.2014.26</ArticleId><ArticleId IdType="pubmed">24710150</ArticleId></ArticleIdList></Reference><Reference><Citation>Selakovic V, Raicevic R, Radenovic L. The increase of neuron-specific enolase in cerebrospinal fluid and plasma as a marker of neuronal damage in patients with acute brain infarction. J. Clin. Neurosci. 2005;12:542&#x2013;547. doi: 10.1016/j.jocn.2004.07.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jocn.2004.07.019</ArticleId><ArticleId IdType="pubmed">15921910</ArticleId></ArticleIdList></Reference><Reference><Citation>Hay E, et al. Cerebrospinal fluid enolase in stroke. J. Neurol. Neurosurg. Psychiatry. 1984;47:724&#x2013;729. doi: 10.1136/jnnp.47.7.724.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.47.7.724</ArticleId><ArticleId IdType="pmc">PMC1027902</ArticleId><ArticleId IdType="pubmed">6747647</ArticleId></ArticleIdList></Reference><Reference><Citation>Papuc E, Rejdak K. Increased cerebrospinal fluid S100B and NSE reflect neuronal and glial damage in Parkinson's disease. Front. Aging Neurosci. 2020;12:156. doi: 10.3389/fnagi.2020.00156.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2020.00156</ArticleId><ArticleId IdType="pmc">PMC7387568</ArticleId><ArticleId IdType="pubmed">32792937</ArticleId></ArticleIdList></Reference><Reference><Citation>Christl J, et al. Association of cerebrospinal fluid S100B protein with core biomarkers and cognitive deficits in prodromal and mild Alzheimer's disease. J. Alzheimers Dis. 2019;72:1119&#x2013;1127. doi: 10.3233/JAD-190550.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-190550</ArticleId><ArticleId IdType="pubmed">31683478</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdo WF, et al. Cerebrospinal fluid analysis differentiates multiple system atrophy from Parkinson's disease. Mov. Disord. 2004;19:571&#x2013;579. doi: 10.1002/mds.10714.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.10714</ArticleId><ArticleId IdType="pubmed">15133823</ArticleId></ArticleIdList></Reference><Reference><Citation>Kepa L. Evaluation of cerebrospinal fluid and plasma neuron-specific enolase (NSE) concentration in patients with purulent, bacterial meningoencephalitis. Przegl. Epidemiol. 2009;63:23&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">19522221</ArticleId></ArticleIdList></Reference><Reference><Citation>Zerr I, et al. Cerebrospinal fluid concentration of neuron-specific enolase in diagnosis of Creutzfeldt&#x2013;Jakob disease. Lancet. 1995;345:1609&#x2013;1610. doi: 10.1016/s0140-6736(95)90118-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(95)90118-3</ArticleId><ArticleId IdType="pubmed">7783539</ArticleId></ArticleIdList></Reference><Reference><Citation>Nygaard O, Langbakk B, Romner B. Neuron-specific enolase concentrations in serum and cerebrospinal fluid in patients with no previous history of neurological disorder. Scand. J. Clin. Lab. Investig. 1998;58:183&#x2013;186. doi: 10.1080/00365519850186562.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00365519850186562</ArticleId><ArticleId IdType="pubmed">9670341</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasuda T, Yanagi T, Mokuno K, Kato K. Neuron-specific enolase (NSE) and S-100b protein in cerebrospinal fluid of patients with cervical spondylosis&#x2013;the relations with MRI findings and the changes of NSE and S-100b protein levels through Glisson's traction. Rinsho Shinkeigaku. 1992;32:1299&#x2013;1301.</Citation><ArticleIdList><ArticleId IdType="pubmed">1301336</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi H, et al. Axonal damage is remarkable in patients with acutely worsening symptoms of compression myelopathy: Biomarkers in cerebrospinal fluid samples. Eur. Spine J. 2018;27:1824&#x2013;1830. doi: 10.1007/s00586-018-5549-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00586-018-5549-5</ArticleId><ArticleId IdType="pubmed">29557051</ArticleId></ArticleIdList></Reference><Reference><Citation>Haque A, Polcyn R, Matzelle D, Banik NL. New insights into the role of neuron-specific enolase in neuro-inflammation, neurodegeneration, and neuroprotection. Brain Sci. 2018 doi: 10.3390/brainsci8020033.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/brainsci8020033</ArticleId><ArticleId IdType="pmc">PMC5836052</ArticleId><ArticleId IdType="pubmed">29463007</ArticleId></ArticleIdList></Reference><Reference><Citation>Pislar A, Bozic B, Zidar N, Kos J. Inhibition of cathepsin X reduces the strength of microglial-mediated neuroinflammation. Neuropharmacology. 2017;114:88&#x2013;100. doi: 10.1016/j.neuropharm.2016.11.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2016.11.019</ArticleId><ArticleId IdType="pubmed">27889490</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinores SA, Rubinstein LJ. Simultaneous expression of glial fibrillary acidic (GFA) protein and neuron-specific enolase (NSE) by the same reactive or neoplastic astrocytes. Neuropathol. Appl. Neurobiol. 1985;11:349&#x2013;359. doi: 10.1111/j.1365-2990.1985.tb00031.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2990.1985.tb00031.x</ArticleId><ArticleId IdType="pubmed">3001557</ArticleId></ArticleIdList></Reference><Reference><Citation>Deloulme JC, et al. Expression of the neuron-specific enolase gene by rat oligodendroglial cells during their differentiation. J. Neurochem. 1996;66:936&#x2013;945. doi: 10.1046/j.1471-4159.1996.66030936.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.1996.66030936.x</ArticleId><ArticleId IdType="pubmed">8769852</ArticleId></ArticleIdList></Reference><Reference><Citation>Haque A, Ray SK, Cox A, Banik NL. Neuron specific enolase: A promising therapeutic target in acute spinal cord injury. Metab. Brain Dis. 2016;31:487&#x2013;495. doi: 10.1007/s11011-016-9801-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11011-016-9801-6</ArticleId><ArticleId IdType="pmc">PMC4864119</ArticleId><ArticleId IdType="pubmed">26847611</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiot A, Lobsiger CS, Boillee S. New insights on the disease contribution of neuroinflammation in amyotrophic lateral sclerosis. Curr. Opin. Neurol. 2019;32:764&#x2013;770. doi: 10.1097/WCO.0000000000000729.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000729</ArticleId><ArticleId IdType="pubmed">31306211</ArticleId></ArticleIdList></Reference><Reference><Citation>Askanas V, Marangos PJ, Engel WK. CSF from amyotrophic lateral sclerosis patients applied to motor neurons in culture fails to alter neuron-specific enolase. Neurology. 1981;31:1196&#x2013;1197. doi: 10.1212/wnl.31.9.1196.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.31.9.1196</ArticleId><ArticleId IdType="pubmed">7196548</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada M, Furukawa Y, Hirohata M. Amyotrophic lateral sclerosis: Frequent complications by cervical spondylosis. J. Orthop Sci. 2003;8:878&#x2013;881. doi: 10.1007/s00776-003-0712-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00776-003-0712-0</ArticleId><ArticleId IdType="pubmed">14648282</ArticleId></ArticleIdList></Reference><Reference><Citation>Teresi LM, et al. Asymptomatic degenerative disk disease and spondylosis of the cervical spine: MR imaging. Radiology. 1987;164:83&#x2013;88. doi: 10.1148/radiology.164.1.3588931.</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/radiology.164.1.3588931</ArticleId><ArticleId IdType="pubmed">3588931</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, et al. The ALSFRS-R: A revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III) J. Neurol. Sci. 1999;169:13&#x2013;21. doi: 10.1016/s0022-510x(99)00210-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0022-510x(99)00210-5</ArticleId><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>